1
|
Pham TNQ, Meziane O, Miah MA, Volodina O, Colas C, Béland K, Li Y, Dallaire F, Keler T, Guimond JV, Lesage S, Cheong C, Haddad É, Cohen ÉA. Flt3L-Mediated Expansion of Plasmacytoid Dendritic Cells Suppresses HIV Infection in Humanized Mice. Cell Rep 2020; 29:2770-2782.e5. [PMID: 31775044 DOI: 10.1016/j.celrep.2019.10.094] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2018] [Revised: 08/29/2019] [Accepted: 10/23/2019] [Indexed: 12/24/2022] Open
Abstract
Plasmacytoid dendritic cells (plasmacytoid DC, pDC) are major IFN-I producers and have been shown to be affected by HIV through ill-defined mechanisms. In this study, we directly assess the role of pDC in early infection, evaluating whether modulating their abundance can alter viral replication. First, HIV infection of humanized mice induces systemic depletion of pDC, and in the presence of soluble FMS-like tyrosine kinase 3 ligand (Flt3L), pDC levels remain elevated. Flt3L significantly delays the onset of viremia and reduces viral replication via a process that is dependent on pDC and mediated through an enhanced early IFN-I response. pDC from Flt3L-treated mice are more prone to express IFN-α following TLR7 stimulation, but this propensity is gradually decreased during infection. In conclusion, maintaining pDC levels and function is key to effective early viral control, and in this context, these findings provide practical insights for anti-HIV strategies and vaccine design.
Collapse
Affiliation(s)
- Tram N Q Pham
- Montréal Clinical Research Institute, Montréal, QC H2W 1R7, Canada.
| | - Oussama Meziane
- Montréal Clinical Research Institute, Montréal, QC H2W 1R7, Canada
| | - Mohammad Alam Miah
- Montréal Clinical Research Institute, Montréal, QC H2W 1R7, Canada; Department of Physiology, Bangladesh Agricultural University, Mymensingh 2202, Bangladesh
| | - Olga Volodina
- Montréal Clinical Research Institute, Montréal, QC H2W 1R7, Canada
| | - Chloé Colas
- Research Center of CHU Sainte-Justine, Montréal, QC H3T 1C5, Canada
| | - Kathie Béland
- Research Center of CHU Sainte-Justine, Montréal, QC H3T 1C5, Canada
| | - Yuanyi Li
- Research Center of CHU Sainte-Justine, Montréal, QC H3T 1C5, Canada
| | | | - Tibor Keler
- Celldex Therapeutics, Hampton, NJ 08827, USA
| | - Jean V Guimond
- Centre de Santé et de Services Sociaux Jeanne-Mance, Montreal, QC H2T 1H4, Canada
| | - Sylvie Lesage
- Department of Immunology-Oncology, Maisonneuve-Rosemont Hospital, Montréal, QC H1T 2M4, Canada; Department of Microbiology, Infectiology and Immunology, Université de Montréal, Montréal, QC H3T 1J4, Canada
| | - Cheolho Cheong
- Montréal Clinical Research Institute, Montréal, QC H2W 1R7, Canada; Department of Microbiology, Infectiology and Immunology, Université de Montréal, Montréal, QC H3T 1J4, Canada
| | - Élie Haddad
- Research Center of CHU Sainte-Justine, Montréal, QC H3T 1C5, Canada; Department of Microbiology, Infectiology and Immunology, Université de Montréal, Montréal, QC H3T 1J4, Canada; Department of Pediatrics, Université de Montréal, Montréal, QC H3T 1J4, Canada
| | - Éric A Cohen
- Montréal Clinical Research Institute, Montréal, QC H2W 1R7, Canada; Department of Microbiology, Infectiology and Immunology, Université de Montréal, Montréal, QC H3T 1J4, Canada.
| |
Collapse
|
2
|
Font-Haro A, Janovec V, Hofman T, Machala L, Jilich D, Melkova Z, Weber J, Trejbalova K, Hirsch I. Expression of TIM-3 on Plasmacytoid Dendritic Cells as a Predictive Biomarker of Decline in HIV-1 RNA Level during ART. Viruses 2018; 10:v10040154. [PMID: 29597250 PMCID: PMC5923448 DOI: 10.3390/v10040154] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2018] [Revised: 03/24/2018] [Accepted: 03/26/2018] [Indexed: 12/12/2022] Open
Abstract
Depletion and functional impairment of circulating plasmacytoid dendritic cells (pDCs) are characteristic attributes of HIV-1-infection. The mechanism of dysfunction of pDCs is unclear. Here, we studied the development of phenotype of pDCs in a cohort of HIV-1-infected individuals monitored before the initiation and during a 9-month follow up with antiretroviral therapy (ART). Using polychromatic flow cytometry, we detected significantly higher pDC-surface expression of the HIV-1 receptor CD4, regulatory receptor BDCA-2, Fcγ receptor CD32, pDC dysfunction marker TIM-3, and the marker of killer pDC, TRAIL, in treatment-naïve HIV-1-infected individuals before initiation of ART when compared to healthy donors. After 9 months of ART, all of these markers approached but did not reach the expression levels observed in healthy donors. We found that the rate of decline in HIV-1 RNA level over the first 3 months of ART negatively correlated with the expression of TIM-3 on pDCs. We conclude that immunogenic phenotype of pDCs is not significantly restored after sustained suppression of HIV-1 RNA level in ART-treated patients and that the level of the TIM-3 expressed on pDCs in treatment naïve patients could be a predictive marker of the rate of decline in the HIV-1 RNA level during ART.
Collapse
Affiliation(s)
- Albert Font-Haro
- Institute of Molecular Genetics of the Czech Academy of Sciences, 14220 Prague, Czech Republic.
- Department of Genetics and Microbiology, Charles University, Faculty of Sciences, BIOCEV, 25242 Vestec, Czech Republic.
- Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, IOCB & Gilead Research Center, 16610 Prague, Czech Republic.
| | - Vaclav Janovec
- Institute of Molecular Genetics of the Czech Academy of Sciences, 14220 Prague, Czech Republic.
- Department of Genetics and Microbiology, Charles University, Faculty of Sciences, BIOCEV, 25242 Vestec, Czech Republic.
- Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, IOCB & Gilead Research Center, 16610 Prague, Czech Republic.
| | - Tomas Hofman
- Department of Genetics and Microbiology, Charles University, Faculty of Sciences, BIOCEV, 25242 Vestec, Czech Republic.
| | - Ladislav Machala
- The Third Faculty of Medicine, Charles University and Hospital Na Bulovce, 18081 Prague, Czech Republic.
| | - David Jilich
- The First Faculty of Medicine, Charles University and Hospital Na Bulovce, 18081 Prague, Czech Republic.
| | - Zora Melkova
- Department of Immunology and Microbiology, Charles University, The First Faculty of Medicine, BIOCEV, 25242 Vestec, Czech Republic.
| | - Jan Weber
- Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, IOCB & Gilead Research Center, 16610 Prague, Czech Republic.
| | - Katerina Trejbalova
- Institute of Molecular Genetics of the Czech Academy of Sciences, 14220 Prague, Czech Republic.
| | - Ivan Hirsch
- Institute of Molecular Genetics of the Czech Academy of Sciences, 14220 Prague, Czech Republic.
- Department of Genetics and Microbiology, Charles University, Faculty of Sciences, BIOCEV, 25242 Vestec, Czech Republic.
- Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, IOCB & Gilead Research Center, 16610 Prague, Czech Republic.
| |
Collapse
|